Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Total Non-Current Liabilities readings, the most recent being $202.6 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 14.35% to $202.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $202.6 million, a 14.35% decrease, with the full-year FY2025 number at $215.8 million, down 12.86% from a year prior.
  • Total Non-Current Liabilities hit $202.6 million in Q4 2025 for Enanta Pharmaceuticals, down from $215.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $256.9 million in Q2 2023 to a low of $30.7 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $209.2 million (2025), compared with a mean of $149.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 17.17% in 2022 and later soared 445.44% in 2023.
  • Enanta Pharmaceuticals' Total Non-Current Liabilities stood at $55.9 million in 2021, then dropped by 17.17% to $46.3 million in 2022, then soared by 409.83% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then dropped by 14.35% to $202.6 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $202.6 million (Q4 2025), $215.8 million (Q3 2025), and $221.5 million (Q2 2025) per Business Quant data.